Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
8,358 people get TEVA articles and Market Currents by email alert.
Get email alerts on TEVA »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
Business Wire (May 14, 2013)
-
-
-
-
-
-
-
-
-
-
Business Wire (May 8, 2013)
-
-
To learn more about Seeking Alpha Pro, click here.
-
Teva's CEO Reviews Management Succession (Transcript)Tue, Jan 3, 2012
-
Teva CEO Discusses Q4 2010 Results - Earnings Call TranscriptTue, Feb 8, 2011 • 1 Comment
-
Teva Pharmaceutical Industries Limited Q2 2010 Earnings Call TranscriptTue, Jul 27, 2010 • 1 Comment
-
Business Wire (May 14, 2013)
-
at CNBC.com (May 9, 2013)
-
at CNBC.com (May 8, 2013)
-
Business Wire (May 8, 2013)
-
Business Wire (May 2, 2013)
-
at CNBC.com (Apr 26, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 23, 2013)
-
at CNBC.com (Apr 11, 2013)
-
Business Wire (Apr 9, 2013)
-
Business Wire (Apr 8, 2013)
-
Business Wire (Apr 8, 2013)
TEVA vs. ETF Alternatives
Company Description
Teva Pharmaceutical Industries Limited (“Teva”) is a global pharmaceutical company that develops, produces and markets generic drugs in all major therapeutic categories. We are the leading generic drug company in the world – with the leading position in the U.S. (in terms of both value and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, March 20, 8:44 AM Teva (TEVA) and Lundbeck (HLUKF.PK) say that their Azilect treatment met its primary endpoint in a trial to assess its effect when used in conjunction with dopamine agonists, which stimulate nerve cells. The combination "provided a statistically significant improvement in the total Unified Parkinsons Disease Rating Scale (UPDRS) score." (PR) Comment! [Healthcare]
- Monday, March 4, 8:48 AM Teva's (TEVA) Milprosa" treatment proved to be "an effective and safe option" for supplementing the progesterone hormone in women undergoing IVF treatment in a Phase III trial. The study is significant for Teva, "because fertility is a meaningful new area of specialization for the company and one in which a significant unmet need exists." Shares +0.2% in Tel Aviv. (PR) 1 Comment [Healthcare]
- Wednesday, February 20, 8:57 AM Teva (TEVA) will be able to launch a generic version of Gilead's (GILD) Viread treatment for HIV and chronic hepatitis B in December 2017 after the companies reached a settlement ahead of a trial that was due to begin today. Gilead sued Teva in 2008 and 2010 for infringing its patents after the latter applied to the FDA to manufacture the drugs. Teva said the patents were invalid. (PR) 1 Comment [Healthcare]
- Thursday, February 14, 3:10 PM Teva Pharmaceutical (TEVA +0.3%) says the FDA has approved its Abbreviated New Drug Application for the generic version of Shire's (SHPG) Adderall XR capsules for the treatment of ADD. Adderall XR had annual sales, including brand and generic sales, of approximately $2B in the U.S. last year. 5 Comments [Healthcare]
- Thursday, February 14, 4:59 AM Teva (TEVA) is facing a bill of up to $2.1B for selling generic versions of Pfizer's (PFE) heartburn drug Protonix before its U.S. patent exclusivity expired in 2011. Teva had already provisioned $670M in Q3 and said this week that the figure could go up by another $1.4B. A trial for Pfizer's claim for damages is due to start in June, while Teva also plans to appeal a jury verdict that upheld Protonix's patent. Comment! [Healthcare]
- Tuesday, February 12, 1:46 PM Shares of Bristol-Myers (BMY -0.7%) slide after a federal judge rules a U.S. patent for its hepatitis B treatment Baraclude is invalid, saying there's clear and convincing evidence that a key claim in the patent is invalid due to obviousness. The ruling opens the door to Teva Pharmaceutical (TEVA +0.4%) selling a competing generic copy. BMY says it's disappointed in the ruling and plans to appeal. Comment! [Healthcare, On the Move]
- Friday, February 8, 1:56 PM Teva Pharmaceutical (TEVA +2.3%) shrugs off a downgrade to Hold at Canaccord to trade higher today. The company has been creeping higher since posting a less-than-stellar Q4 earnings report yesterday morning, perhaps in part due to comments during its conference call that sales of its MS drug Copaxone rose by 14% to $1.1B. Read more here: Earnings Call Transcript. Comment! [On the Move, Healthcare, Earnings]
- Thursday, February 7, 9:03 AM More on Teva (TEVA -2.1%) Q4: net profit -37% to $320M as revenue falls 7.5%. U.S. sales -14% to $2.6B amid a sharp fall in Provigil (sleep disorder) due to generic competition. Copaxone global revenues +14% to $1.1B, but faces increasing competition. Expects to launch 23 generic drugs in 2013, as in 2012. Reiterates 2013 revenue forecast of $19.5-20.5B and adjusted EPS of $4.85-5.15. Declares dividend of 1.15 shekels (31 cents) a share, +15% from Q3. 2 Comments [Healthcare, Earnings, Dividends]
- Thursday, February 7, 7:02 AM Teva Pharma (TEVA): Q4 EPS of $1.32 misses by $0.01. Revenue of $5.2B misses by $0.06B. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
- Thursday, February 7, 12:05 AM Notable earnings before Thursday’s open: AAP, ALU, BG, CCE, CI, CS, CTSH, EXC, FLIR, FLO, GPK, HLSS, HOT, INGR, KKR, MFC, MPW, MWW, NBL, NNN, NYT, ONNN, OZM, PM, PMT, PTEN, S, SBH, SIAL, SNE, SNI, SPH, SQNS, TDC, TEVA, XYL Comment! [Earnings]
- Wednesday, February 6, 5:30 PM Notable earnings before Thursday’s open: AAP, ALU, BG, CCE, CI, CS, CTSH, EXC, FLIR, FLO, GPK, HLSS, HOT, INGR, KKR, MFC, MPW, MWW, NBL, NNN, NYT, ONNN, OZM, PM, PMT, PTEN, S, SBH, SIAL, SNE, SNI, SPH, SQNS, TDC, TEVA, XYL 1 Comment [Earnings]
- Wednesday, January 30, 2:16 PM Procter & Gamble (PG +0.4%) and Teva Pharmaceuticals (TEVA +0.1%) break ground on a new $90M plant in India through their joint venture in the region. The new plant will support the growing demand in Asia for non-prescription health care products. 1 Comment [Consumer]
- Wednesday, January 9, 6:04 PM Teva (TEVA) files a petition with the FDA requesting the agency task an outside panel to evaluate the safety of Biogen's (BIIB) multiple sclerosis drug, BG-12, before approval due to concerns over potential risks to the kidney. The drug is a potential competitor to TEVA's Copaxone, and if the request is granted, the drug's launch could be delayed. 2 Comments [Healthcare]
- Friday, January 4, 5:57 AM Eli Lilly (LLY), which is suffering from a massive patent cliff and faces another one in 2017, could keep marketing exclusivity for its blockbuster Alimta lung cancer drug until 2022 rather than 2016 if it wins a case over a "method-of-use" patent on the way the multibillion dollar selling treatment is administered. Such IP is usually not upheld, although some experts believe that the Alimta case is different. Generic firms such as Teva (TEVA) argue otherwise. 3 Comments [Healthcare, Top Stories]
- Thursday, January 3, 9:31 AM Bayer HealthCare completes the acquisition of Teva's (TEVA +0.1%) U.S.-based animal health business after receiving the necessary regulatory approvals. Teva will receive up to $145M following the achievement of manufacturing and sales targets. The sale is no doubt part of the Israeli company's restructuring. Comment! [Healthcare]
- Friday, December 28, 2012, 11:22 AM Mylan (MYL -0.4%) says its partner Famy Care has received final FDA approval for its Abbreviated New Drug Application for Levonorgestrel and Ethinyl Estradiol Tablets, a generic version of Teva Pharmaceutical's (TEVA +0.6%) contraception product Nordette. MYL plans to begin shipping the product immediately. Comment! [Healthcare]
-
Retail Investor
$DNDN $AMRN $TEVA $ARNA $CLSN $SPY $TARO Posts Strong Results -> http://bit.ly/THNRyQ - View all 0 replies
-
- View all 0 replies
-
neobliviscar
$TEVA- closing personal position. Sold 40 Jan $37.5 puts for about 0.75 & buying back at 0.05. I know one or two others were in with me. - View all 2 replies
-
-
SKS1586: Awesome. I entered around same time by selling Jan14 50Puts (longer horizon & dividend collection). Your strategy looks better now.
-
- View all 4 replies
-
VFC's Stock House: Haha, SmokeyRose - I don't know much more than anyone else, except that $INO is up about twenty five percent this year. Nice. Good luck!
-
-
- View all 0 replies
-
- View all 7 replies
-
-
Julius Ferraro: Sold some 37.5 puts. Nothing in this market is cheap anymore
-
neobliviscar
$TEVA . Had to wait for this one to bottom. Selling Jan Puts at this level. Be happy to go long here & conv to Cov Call later. - View all 5 replies
-
chopchop0: I decided to bite on a long position today. Seems insanely cheap at 7x forward earnings.
-
neobliviscar: P/E can be dang w/ drug co., but reviewing what they've got & the likelyhood of 'will have', seemed very safe risk/reward $35-$37.5 buy zone
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 2 replies
-
losbronces: Court ruled for Pronova (PRON.OS, PVNAY), regarding patents for Lovaza against PRX and TEVA. -
Mercy Jimenez: thanks losbronces; TEVA =hands full; also saw FDA Warning About a Fake Version Of Teva's ADHD Drug Adderall http://bit.ly/KFik9H
-
- View all 3 replies
-
-
Mathieu Malecot: i am not long MSFT. long NATDF, NOK, INTC and AXPW. looking at TEVA/ MSTF and picked up some miners for the shorter term.
-
Brad Prigmore
PPG and TEVA killing it the last two days. Love being ahead of the curve...now if somebody would just read my articles. - View all 4 replies
-
Brad Prigmore: And honestly, you probably read the first couple articles and thats it. I am learning certain types of articles make more money..
-
neobliviscar: For comrade idea exchange & fun, I share personal trades. Not those of our Fund. Why write? It will be interesting to see if you are alumnus
-
- View all 3 replies
-
-
-
- View all 2 replies
-
Mercy Jimenez: Agree added today @$43.50 before the FDA announcement. It also has big upside in Asia: http://reut.rs/wUbQdS
-
Alex Rasmussen: Thanks Mercy. Part of the global deleveraging has to be government support for generic drug manufacturers. The consumer only benefits.
-
- View all 1 replies
-
-
- View all 1 replies
-
-
Dividend Sheet
Best Healthcare Stock Picks For 2012: http://bit.ly/w32xHl + $MRK $NVS $STJ $TEVA $TMO $CELG $GILD - View all 2 replies
-
-
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 2 replies
-
-
-
- View all 4 replies
-
bigazul: If I saw that 38-39 gap filled, I'd make a buy there; then I'd wait to fill out the rest.
-
-
- View all 1 replies
-
noah zeiler: Dr. Frost has a new company project....Opko Health (OPK)...With Frost at the helm...This company is a strong buy. Due the research.
-
- View all 2 replies
-
-